Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q1 2022 · 10-Q
Revenue$417.60M$417.60M+22.6% vs Q1 2021 Net Income$41.78M$41.78M+1.7% vs Q1 2021 EPS Diluted$3.59$3.59+3.8% vs Q1 2021 Gross Profit$302,286,000+21.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flow$43,673,000−33.1% Free Cash Flowderived$40,664,000−33.0% Margins · derivedGross margin72.4%−0.6 pt vs Q1 2021
Operating margin13.2%−2.3 pt vs Q1 2021
Net margin10.0%−2.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 2, 2022 · 32 d after period end